Hormone replacement therapy is associated with gastro-oesophageal reflux disease: a retrospective cohort study

BMC Gastroenterology

A Pali S Hungin²  Douglas Wilson¹  James M Mason¹  Helen Close¹ 

[1] Durham Clinical Trials Unit, Queen’s Campus, Wolfson Research Institute, University of Durham, University Boulevard, Stockton-on-Tees, TS17 6BH, UK;School of Medicine and Health, Queen’s Campus, Wolfson Research Institute, University of Durham, University Boulevard, Stockton-on-Tees, TS17 6BH, UK

关键词: Menopause;    Hormone replacement therapy;    Gastro-oesophageal reflux disease;   

Others  :  1113061
DOI  :  10.1186/1471-230X-12-56

 received in 2011-10-10, accepted in 2012-05-29,  发布年份 2012

【 摘 要 】

Background

Oestrogen and progestogen have the potential to influence gastro-intestinal motility; both are key components of hormone replacement therapy (HRT). Results of observational studies in women taking HRT rely on self-reporting of gastro-oesophageal symptoms and the aetiology of gastro-oesophageal reflux disease (GORD) remains unclear. This study investigated the association between HRT and GORD in menopausal women using validated general practice records.

Methods

51,182 menopausal women were identified using the UK General Practice Research Database between 1995–2004. Of these, 8,831 were matched with and without hormone use. Odds ratios (ORs) were calculated for GORD and proton-pump inhibitor (PPI) use in hormone and non-hormone users, adjusting for age, co-morbidities, and co-pharmacy.

Results

In unadjusted analysis, all forms of hormone use (oestrogen-only, tibolone, combined HRT and progestogen) were statistically significantly associated with GORD. In adjusted models, this association remained statistically significant for oestrogen-only treatment (OR 1.49; 1.18–1.89). Unadjusted analysis showed a statistically significant association between PPI use and oestrogen-only and combined HRT treatment. When adjusted for covariates, oestrogen-only treatment was significant (OR 1.34; 95% CI 1.03–1.74). Findings from the adjusted model demonstrated the greater use of PPI by progestogen users (OR 1.50; 1.01–2.22).

Conclusions

This first large cohort study of the association between GORD and HRT found a statistically significant association between oestrogen-only hormone and GORD and PPI use. This should be further investigated using prospective follow-up to validate the strength of association and describe its clinical significance.

【 授权许可】

   
2012 Close et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Klauser AG, Schindlbeck N, Muller-Lissner SA: Symptoms in gastro-oesophageal reflux disease. Lancet 1990, 335(8683):205-208.
• [2]Ruth M, Mansson I, Sandberg N: The prevalence of symptoms suggestive of esophageal disorders. Scand J Gastroenterol 1991, 6:73-81.
• [3]Locke GR, Talley NJ, Fett SL, et al.: Prevalence and clinical spectrum of Gastroesophageal reflux: a population based study in Olmsted County, Minnesota. Gastroenterology 1997, 112:1448-1456.
• [4]He J, Ma X, Zhao Y, Wang R, Yan X, Yan H, Yin P, Kang X, Fang J, Hao Y, Li Q, Dent J, Sung J, Zou D, Wallander M, Johansson S, Liu W, Li Z: A population-based survey of the epidemiology of symptom-defined gastroesophageal reflux disease: the Systematic Investigation of Gastrointestinal Diseases in China. Gastroenterology 2010, 10:94.
• [5]Mason J, Hungin APS: Review article: GORD – the health economic implications. Aliment Pharmacol Ther 2005, 22(Suppl. 1):20-31.
• [6]Younes Z, Johnson DA: Diagnostic evaluation in gastroesophageal reflux disease. Gastroenterol Clin N Am 1999, 28:809-830.
• [7]Eloubeidi MA, Provenzale D: Health-related quality of life and severity of symptoms in patients with Barrett’s esophagus and gastroesophageal reflux disease patients without Barrett’s esophagus. Am J Gastroenterol 2000, 95:1881-1887.
• [8]Solaymani-Doraran M, Logan RF, West J, et al.: Mortality associated with Barrett’s esophagus and gastroesophageal reflux disease diagnoses-a population-based cohort study. Am J Gastroenterol 2005, 100:2616-2621.
• [9]Cameron AJ, Lagergren J, Henriksson C, et al.: Gastrooeophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 2002, 122:55-59.
• [10]Ruigomez A, Garcia Rodriguez LA, Wallander MA, et al.: Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther 2004, 20:751-760.
• [11]Nilsson M, Johnsen R, Ye W, et al.: Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux. Gut 2004, 53:1730-1735.
• [12]Nilsson M, Johnsen R, Ye W, et al.: Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. Jama 2003, 290:66-72.
• [13]Smout AJPM: Gastro-oesophageal reflux disease: Pathogenesis and Diagnosis. In Evolving concepts in Gastrointestinal Motility. Edited by Champion MC, Orr WC. Blackwell Science, Oxford, England; 1996:46-63.
• [14]Van Thiel DH, Gavaler JS, Stremple J: Lower esophageal sphincter pressure in women using sequential oral contraceptives. Gastroenterology 1976, 71:232-234.
• [15]Singh S, Poulsom R, Longcroft JM, et al.: Is cyclical bowel habit mediated by female sex hormones? Eur J Gastroenterol Hepatol 1994, 6:925-930.
• [16]Bruce L, Faiz B: Progesterone effects on three regional gastrointestinal tissues. Life Sci 1979, 25:729-734.
• [17]Turnbull GK, Thompson DG, Day S, et al.: Relationship between symptoms, menstrual cycle and orocaecal transit in normal and constipated women. Gut 1989, 30:30-34.
• [18]Van Thiel DH, Wald A: Evidence refuting a role for increased abdominal pressure in the pathogenesis of the heartburn associated with pregnancy. Am J Obstet Gynaecol 1981, 140:420-422.3.
• [19]Menon S, Trudgill N: Is hormone replacement therapy associated with reflux oesophagitis, Barrett’s oesophagus and oesophageal cancer? Gut 2010, 59(Suppl III):A117.
• [20]Nordenstedt H, Zheng Z, Cameron AJ, et al.: Postmenopausal hormone therapy as a risk factor for gastroesophageal reflux symptoms among female twins. Gastroenterology 2008, 134(4):921-928.
• [21]Zheng Z, Margolis KL, Liu S, et al.: Effects of estrogen with and without progestin and obesity on symptomatic gastroesophageal reflux. Gastroenterology 2008, 135(1):72-81.
• [22]Jacobson BC, Moy B, Colditz GA, et al.: Postmenopausal hormone use and symptoms of gastroesophageal reflux. Arch Intern Med 2008, 168(16):1798-1804.
• [23]Alvarez-Sánchez A, Rey E, Achem SR, et al.: Does progesterone fluctuation across the menstrual cycle predispose to gastroesophageal reflux? Am J Gastroenterol 1999, 6:1468-1471.
• [24]The General Practice Research Database. , ; www.gprd.com webcite
• [25]El-Serag-Hill C, Jones R: Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care, using the UK General Practice Research Database. Aliment Pharmacol Ther 2009, 29:470-480.
• [26]: Communities and Local Government. Communities and neighbourhoods, Indices of Deprivation 2008: PCT Summaries ID. , ; 2008.
• [27]Zervou S, Klentzeris LD, Old RW: Nitric oxide synthase expression and steroid regulation in the uterus of women with menorrhagia. Mol Hum Reprod 1999, 5:1048-1054.
• [28]Nuedling S, Kahlert S, Loebbert K, et al.: 17-Beta-estradiol stimulates expression of endothelial and inducible NO synthase in rat myocardium in-vitro and in-vivo. Cardiovasc Res 1999, 43:666-674.
• [29]Cummings SR, Etttinger B, Delmas PD, et al.: The effects of tibolone in older postmenopausal women. NEJM 2008, 359:697-708.
• [30]Bakken K, Eggen AE, Lund E: Side-effects of hormone replacement therapy and influence on pattern of use among women aged 45–64 years. The Norwegian Women and Cancer (NOWAC) study 1997. Acta Obstetricia et Gynecologica Scandinavica 2004, 83(9):850-856.
• [31]Hall P, Ploner A, Bjohle J, Hunag F, Lin C, Liu E, Miller L, Nordgren H, Pawitan Y, Shaw P, Skoog L, Smeds J, Wedren S, Ohd J, Bergh J: Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Medicine 2006, 4:16. BioMed Central Full Text
• [32]Talley NJ, Weaver Al, Zinsmeister AR, et al.: Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992, 136:165-177.
• [33]Studd J, et al.: HRT and long-term compliance: The efficacy and safety of Menorest. Int J Gynecol Obstet 1996, 52(Suppl 1):S21-S25.